MENU

MBIO Stock Mustang Bio (MBIO, $2.78) Aroon Indicator entered a Downtrend on February 07, 2025.

A.I.dvisor
at Tickeron.com
Loading...
MBIO - Mustang Bio Inc
Aroon signal
Bearish Trend
Odds of DOWN Trend
Tickeron
Aroon signal
Price: $2.78
Daily change: -$0.14 (-4.79%)
Daily volume: 75.7K
Capitalization: $3.6M
Industry: Biotechnology
For the last three days, A.I.dvisor has detected that MBIO's AroonDown red line is above 70 while the AroonUp green line is below 30 for three straight days. This move could indicate a strong downtrend ahead for MBIO, and traders may view it as a Sell signal for the next month. Traders may consider selling the stock or exploring put options. A.I.dvisor backtested this indicator and found 393 similar cases, of which were successful. Based on this data, the odds of success are

MBIO in -7.64% downward trend, sliding for three consecutive days on February 07, 2025

Moving lower for three straight days is viewed as a bearish sign. Keep an eye on this stock for future declines. Considering data from situations where MBIO declined for three days, in of 360 cases, the price declined further within the following month. The odds of a continued downward trend are .

Price Prediction Chart

Technical Analysis (Indicators)

Bearish Trend Analysis

The Aroon Indicator for MBIO entered a downward trend on February 18, 2025. This could indicate a strong downward move is ahead for the stock. Traders may want to consider selling the stock or buying put options.

Bullish Trend Analysis

The RSI Indicator shows that the ticker has stayed in the oversold zone for 9 days. The price of this ticker is presumed to bounce back soon, since the longer the ticker stays in the oversold zone, the more promptly an Uptrend is expected.

The Moving Average Convergence Divergence (MACD) for MBIO just turned positive on February 12, 2025. Looking at past instances where MBIO's MACD turned positive, the stock continued to rise in of 43 cases over the following month. The odds of a continued upward trend are .

Following a 3-day Advance, the price is estimated to grow further. Considering data from situations where MBIO advanced for three days, in of 221 cases, the price rose further within the following month. The odds of a continued upward trend are .

Fundamental Analysis (Ratings)

The Tickeron Valuation Rating of (best 1 - 100 worst) indicates that the company is significantly overvalued in the industry. This rating compares market capitalization estimated by our proprietary formula with the current market capitalization. This rating is based on the following metrics, as compared to industry averages: P/B Ratio (31.746) is normal, around the industry mean (12.604). P/E Ratio (0.000) is within average values for comparable stocks, (85.387). Projected Growth (PEG Ratio) (0.000) is also within normal values, averaging (1.581). MBIO has a moderately low Dividend Yield (0.000) as compared to the industry average of (0.013). P/S Ratio (0.000) is also within normal values, averaging (252.111).

The Tickeron Price Growth Rating for this company is (best 1 - 100 worst), indicating slightly worse than average price growth. MBIO’s price grows at a lower rate over the last 12 months as compared to S&P 500 index constituents.

The Tickeron PE Growth Rating for this company is (best 1 - 100 worst), pointing to worse than average earnings growth. The PE Growth rating is based on a comparative analysis of stock PE ratio increase over the last 12 months compared against S&P 500 index constituents.

The Tickeron SMR rating for this company is (best 1 - 100 worst), indicating weak sales and an unprofitable business model. SMR (Sales, Margin, Return on Equity) rating is based on comparative analysis of weighted Sales, Income Margin and Return on Equity values compared against S&P 500 index constituents. The weighted SMR value is a proprietary formula developed by Tickeron and represents an overall profitability measure for a stock.

The Tickeron Profit vs. Risk Rating rating for this company is (best 1 - 100 worst), indicating that the returns do not compensate for the risks. MBIO’s unstable profits reported over time resulted in significant Drawdowns within these last five years. A stable profit reduces stock drawdown and volatility. The average Profit vs. Risk Rating rating for the industry is 94, placing this stock worse than average.

View a ticker or compare two or three
MBIO
Daily Signalchanged days ago
Gain/Loss if bought
Show more...
Ad is loading...
A.I.Advisor
published price charts
A.I. Advisor
published General Information

General Information

a clinical-stage biopharmaceutical company which develops novel immunotherapy''s

Industry Biotechnology

Profile
Fundamentals
Details
Industry
Pharmaceuticals Major
Address
377 Plantation Street
Phone
+1 781 652-4500
Employees
80
Web
https://www.mustangbio.com